Bellini provided an overview of BELLUS Health Inc., including its core capability of identifying and developing innovative drug candidates. Its lead drug candidate, BLU-5937, is a potentially best-in-class P2X3 antagonist for chronic cough that has shown positive preclinical efficacy and a strong safety profile. BELLUS also has a balanced pipeline including three partnered mid-stage programs. Upcoming milestones include completing IND-enabling studies for BLU-5937 and progressing partnered programs.